## Author's Accepted Manuscript

Ascorbic acid repletion: A possible therapy for diabetic macular edema?

James M. May



 PII:
 S0891-5849(16)00070-8

 DOI:
 http://dx.doi.org/10.1016/j.freeradbiomed.2016.02.019

 Reference:
 FRB12759

To appear in: Free Radical Biology and Medicine

Received date: 5 January 2016 Revised date: 10 February 2016 Accepted date: 16 February 2016

Cite this article as: James M. May, Ascorbic acid repletion: A possible therapy for diabetic macular edema?, *Free Radical Biology and Medicine*, http://dx.doi.org/10.1016/j.freeradbiomed.2016.02.019

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## ACCEPTED MANUSCRIPT

Ascorbic Acid Repletion: A Possible Therapy for Diabetic Macular Edema?

James M. May

Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232-6303 \*Running title: Ascorbate and macular edema

To whom correspondence should be addressed: James May, M.D. 7465 Medical Research Building IV, Vanderbilt University School of Medicine, Nashville, TN 37232-0475. Tel. (615) 936-1653; Fax: (615) 936-1667. E-mail: james.may@vanderbilt.edu

Abbreviations: AGE, advanced glycation end-products; eNOS, endothelial nitric oxide synthase; HMGB1, high mobility group box 1 protein; HUVECs, human umbilical vein endothelial cells; iNOS, inducible nitric oxide synthase; NOX, NADPH oxidase; L-NAME (N<sup> $\phi$ </sup>-nitro-L-arginine methyl ester); NO, nitric oxide; RAGE, receptor for advanced glycation end-products; RNS, reactive nitrogen species; ROS, reactive oxygen species; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; VEGF, vascular endothelial growth factor;

## Abstract

Macular edema poses a significant risk for visual loss in persons with diabetic retinopathy. It occurs when plasma constituents and fluid leak out of damaged retinal microvasculature in the area of the macula, causing loss of central vision. Apoptotic loss of pericytes surrounding capillaries is perhaps the earliest feature of diabetic vascular damage in the macula, which is also associated with dysfunction of the endothelium and loss of the otherwise very tight endothelial permeability barrier. Increased oxidative stress is a key feature of damage to both cell types, mediated by excess superoxide from glucose-induced increases in Download English Version:

## https://daneshyari.com/en/article/8267924

Download Persian Version:

https://daneshyari.com/article/8267924

Daneshyari.com